Share Twitter LinkedIn Facebook Email Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trial for PARP-Inhibitor for Germ-Line in BRCA1 & 2 | Response Rate Doubled Comparing Talazoparib at Annual Meeting 2018
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer Breast 4 Mins Read